CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
November 18, 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical a
Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
November 12, 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected from a competitive field of numerous companies as one of
HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 23, 2024 10:30 ET
|
HiberCell, Inc.
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce...
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
October 07, 2024 07:00 ET
|
Cybrexa Therapeutics
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
June 26, 2024 10:52 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH's distributor
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
June 17, 2024 09:50 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation.
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
June 05, 2024 15:12 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
“Collaboration in clinical trials ensures data integrity and safety, advancing both organizations' missions and improving patient care,” says Dr. Jennifer
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
May 28, 2024 08:00 ET
|
HiberCell, Inc.
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
April 05, 2024 10:00 ET
|
HiberCell, Inc.
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
March 27, 2024 08:00 ET
|
Vector Pharma FZCO; Oncopeptides AB
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa